Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Starna Therapeutics Closes $40M Series B+ Round to Advance In Vivo CAR-T and Extrahepatic mRNA Delivery Platforms

Fineline Cube May 11, 2026
Company Deals

CureGene Pharmaceutical Secures RMB 300 Million Series C to Advance Global Clinical Pipeline

Fineline Cube May 9, 2026
Company Deals

Hengrui Pharmaceuticals Expands Greater Bay Area Presence with Hong Kong Office Launch and Cancer Foundation Partnership

Fineline Cube May 9, 2026
Company Deals

Fosun Pharma Secures Exclusive China Rights to InxMed’s FAK Inhibitors for Solid Tumor Treatment

Fineline Cube May 9, 2026
Company Deals

Harbour BioMed Joins $165M Cross Financing Round for Windward Bio to Advance Ultra-Long-Acting TSLP Immunotherapies

Fineline Cube May 8, 2026
Policy / Regulatory

NHSA Launches 2026 NRDL Adjustment with Expanded Eligibility Criteria and Revised Weight Standards

Fineline Cube May 11, 2026
Company Drug

Henlius Biotech Expands European Footprint with Two Additional EC Approvals for HanSiZhuang PD-1 Inhibitor

Fineline Cube May 11, 2026
Company Drug

Henlius Biotech Receives FDA Clearance for Phase I Trial of HLX05-N Cetuximab Biosimilar in Metastatic Colorectal Cancer

Fineline Cube May 11, 2026
Company Deals

Salubris Partners with Anlong Bio for Small Nucleic Acid Drugs in Hypertension

Fineline Cube Oct 28, 2022

China’s Shenzhen Salubris Pharmaceuticals Co., Ltd (SHE: 002294) has entered into a partnership with Beijing...

Policy / Regulatory

Shanghai Launches Inhaled COVID-19 Vaccine Booster Program

Fineline Cube Oct 28, 2022

On October 25, Shanghai began accepting patient reservations for the inhalable recombinant COVID-19 vaccine (adenovirus...

Company Drug

Ocumension Initiates Second Phase III Denali Study for OT-301 in US

Fineline Cube Oct 27, 2022

China-based Ocumension Therapeutics (HKG: 1477) announced the initiation of a second Phase III Denali study...

Company R&D

Nankai University Establishes Postgraduate Practice Base with China Resources Biopharma

Fineline Cube Oct 27, 2022

The College of Pharmacy at Nankai University has established a postgraduate practice base at the...

Company Deals

Yiming and WZ Biosciences Collaborate on mRNA Process Platform

Fineline Cube Oct 27, 2022

China-based Yiming (Beijing) Cell Biotechnology Co., Ltd, also known as Ubrigene, and compatriot firm WZ...

Company Drug

BeiGene’s Brukinsa Receives Multiple Marketing Approvals in Latin America

Fineline Cube Oct 27, 2022

China-based biotech BeiGene Inc. (HKG: 6160, SHA: 688235, NASDAQ: BGNE) announced receiving multiple marketing approvals...

Company Drug

Zhaoke Ophthalmology Completes Enrollment for Intrarosa Phase III Trial

Fineline Cube Oct 27, 2022

China-based Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) subsidiary Zhaoke Ophthalmology Ltd (HKG: 6622) has completed...

Company Deals

JW Therapeutics Partners with 2seventy bio to Develop Cell Therapy Platform

Fineline Cube Oct 27, 2022

China-based JW Therapeutics (HKG: 2126) has entered into a partnership with US firm 2seventy bio...

Company Drug

Ascletis Pharma Files IND for Monkeypox Antiviral ASC10 with FDA

Fineline Cube Oct 27, 2022

China-based Ascletis Pharma Inc. (HKG: 1672) announced the submission of an Investigational New Drug (IND)...

Company Drug

Simcere Receives FDA Clearance for Clinical Study of SIM0237

Fineline Cube Oct 27, 2022

China-based Simcere Pharmaceutical Group (HKG: 2096) announced that it has received clearance from the US...

Company

Ping An Life Insurance Reports Q3 Results, Advances Healthcare Strategy

Fineline Cube Oct 27, 2022

Ping An Life Insurance Company of China Ltd released its 2022 Q3 financial report, showing...

Company Drug

United Labs Gains NMPA Approval for Ozempic Biosimilar IND

Fineline Cube Oct 27, 2022

Hong Kong-based United Laboratories International Holdings Ltd (HKG: 3933) announced that the National Medical Products...

Policy / Regulatory

China’s NMPA Issues New Drug Recall Management Measures

Fineline Cube Oct 27, 2022

The National Medical Products Administration (NMPA) has released the “Drug Recall Management Measures,” which took...

Company Medical Device

AccuMedical’s Blood Flow-Guided Stent Wins NMPA Approval for Brain Aneurysms

Fineline Cube Oct 27, 2022

AccuMedical Beijing Ltd has secured approval from China’s National Medical Products Administration (NMPA) for its...

Company Deals

InxMed and Huaota Bio Partner to Develop Novel Solid Tumor Combination Therapy

Fineline Cube Oct 27, 2022

China-based InxMed (Nanjing) Co., Ltd has entered into a strategic partnership with Shanghai Huaota Biopharmaceutical...

Company Deals

LEPU ScienTech Medical Technology Sets IPO Price Range Ahead of Hong Kong Listing

Fineline Cube Oct 27, 2022

China-based LEPU ScienTech Medical Technology (Shanghai) Co., Ltd is gearing up for an initial public...

Company

WuXi AppTec Posts Stellar Q3 2022 Results with 209% Profit Surge

Fineline Cube Oct 27, 2022

China-based WuXi AppTec Co., Ltd (SHA: 603259, HKG: 2359) has released its Q3 2022 financial...

Company Drug

OriginCell’s CAR-T Therapy Receives FDA Orphan Drug Designation for Multiple Myeloma

Fineline Cube Oct 26, 2022

Shanghai-based tumor immunotherapy specialist OriginCell Therapeutics has announced that its investigational autologous chimeric antigen receptor...

Company

Novartis Q3 Revenues Rise 4% YOY; China Sales Expand Despite COVID Lockdowns

Fineline Cube Oct 26, 2022

Swiss pharmaceutical giant Novartis (NYSE: NVS) has reported a 4% year-on-year (YOY) increase in global...

Company Deals

ImmVira Secures Series C+ Financing to Advance Oncolytic Virus and Exosome Programs

Fineline Cube Oct 26, 2022

China-based biotech ImmVira has successfully secured its Series C+ financing, entering into agreements with a...

Posts pagination

1 … 607 608 609 … 663

Recent updates

  • GSK Partners with Sino Biopharmaceutical’s CTTQ Subsidiary to Commercialize Bepirovirsen in China’s Hepatitis B Market
  • Starna Therapeutics Closes $40M Series B+ Round to Advance In Vivo CAR-T and Extrahepatic mRNA Delivery Platforms
  • Henlius Biotech Expands European Footprint with Two Additional EC Approvals for HanSiZhuang PD-1 Inhibitor
  • Henlius Biotech Receives FDA Clearance for Phase I Trial of HLX05-N Cetuximab Biosimilar in Metastatic Colorectal Cancer
  • MicroPort CardioFlow Secures CE Mark for ENO Series Pacemakers with Advanced LBBAP Capability
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Others

GSK Partners with Sino Biopharmaceutical’s CTTQ Subsidiary to Commercialize Bepirovirsen in China’s Hepatitis B Market

Company Deals

Starna Therapeutics Closes $40M Series B+ Round to Advance In Vivo CAR-T and Extrahepatic mRNA Delivery Platforms

Company Drug

Henlius Biotech Expands European Footprint with Two Additional EC Approvals for HanSiZhuang PD-1 Inhibitor

Company Drug

Henlius Biotech Receives FDA Clearance for Phase I Trial of HLX05-N Cetuximab Biosimilar in Metastatic Colorectal Cancer

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.